Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback